MoonLake Immunotherapeutics’ vague data on its autoimmune candidate draws criticism
read at STAT ↗Negative
Adam Feuerstein notes that MoonLake Immunotherapeutics announced "positive" results for its autoimmune drug candidate but released data that is difficult to interpret.
He reminds readers that biotech firms typically share detailed results when the data are strong, and that a lack of clarity can be a warning sign for future success.
Feuerstein points out that MoonLake has shown this pattern repeatedly, making the claim of positivity essentially meaningless.
The commentary appears in a STAT+ opinion piece and is available to subscribers only.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?”
read at STAT ↗495 words · retrieved Aug 11
comments(0)
5-min edit window · permanent after that